Category

Research
This article originally published on Multiple Myeloma Toady ABSTRACT Multiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to an increasing subset of patients living with long-term...
Continue Reading
This article was originally published on Docwire News Sarah Holstein, MD, PhD, associate professor of medicine in the Division of Oncology & Hematology at the University of Nebraska Medical Center, discusses the multiple myeloma (MM) treatment pipeline and how the introduction of these agents may change the treatment landscape. In part two of this interview...
Continue Reading
This article was originally posted on Docwire News. DocWire News sat down with Saad Usmani, M.D., MBA, FACP to discuss an indirect treatment comparison study which assesses DARZALEX® (daratumumab) Plus Lenalidomide and Dexamethasone (D-Rd) and Bortezomib-Containing Regimens in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma. To continue reading this article on Docwire News.
Continue Reading
This article was originally published on Docwire News Nina Shah, MD, an associate professor in the Department of Medicine at the University of California, San Francisco, discusses immunotherapy agents in the pipeline for multiple myeloma (MM) and how the potential approval of these agents could change the treatment landscape and advance combination therapy. Watch part...
Continue Reading
This article was originally published on Targeted Oncology The multiple myeloma treatment paradigm has seen an assortment of therapeutic advances in recent years with agents that have demonstrated the ability to extend survival in patients and improving disease outcomes. However, the severity of the disease continues to linger without a cure, calling for oncologists to...
Continue Reading
This article was originally published on The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...
Continue Reading
This article was originally posted on Strathroy Age Dispatch Multiple myeloma was practically a death sentence when Joanne Ternovan was diagnosed. Like many people who had this incurable cancer of the plasma cells, she was given three years to live. That was 22 years ago. “I didn’t think I was going to make it this...
Continue Reading
This was originally published by News Medical Life Sciences By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. The study will be carried out at Beaumont Hospital Dublin and run through...
Continue Reading
This post was originally published by Cure Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology. “Limited studies describing the impact of COVID-19 both in the (United States) and abroad suggest...
Continue Reading
This post was originally published by Targeted Oncology C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape. Landgren thinks the field is about to reach its potential since there are several...
Continue Reading
1 3 4 5 6 7 8

Floor 7, 90 The Terrace
Wellington Central
New Zealand